Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Walsall Hospitals NHS Trust Goes Live With Horizon Enterprise Visibility From Mckesson, UK
Walsall Hospitals NHS Trust has "gone-live" with Horizon Enterprise Visibility; a visual control system designed specifically for hospitals, from healthcare IT solutions and services specialists, McKesson. Via real-time access to patient information, Walsall will be using Horizon Enterprise Visibility to improve re efficiency and bed utilisation to reduce costs and improve the quality of patient care.

CytRx Reports Favorable Progress Update For Its Pivotal Phase 2 Trial With Tamibarotene As A Third-Line Treatment For Acute Promyelocytic Leukemia
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, provided a favorable progress update for its ongoing Phase 2 STAR-1 registration clinical trial to evaluate the efficacy and safety of orally administered tamibarotene as a third-line treatment for acute promyelocytic leukemia (APL).
News of the day
Idaho Technology Gains Army Approval Of Platinum Path™ Extraction Kit For Biological Pathogen Detection Program
Idaho Technology, Inc. has received the support of the U.S. Army Test and Evaluation Command (ATEC) for use of the Platinum Path™ Extraction Kit (PPEK) with the Joint Biological Agent Identification and Diagnostic System (JBAIDS).
Medical Devices

American Diabetes Association Related To Studies Published In Diabetelogia Suggesting Possible Link Between Insulin Glargine And Cancer

Diabetelogia, the journal of the European Association for the Study of Diabetes (EASD), published a series of research papers today examining a possible link between insulin glargine (brand name, Lantus) and cancer. Findings from these research papers are conflicting and inconclusive, and the American Diabetes Association cautions against over-reaction until more information is available. Four different population based studies were reported and published in Diabetelogia and the data within these studies and between these studies are conflicting and confusing. Until more information is available, the American Diabetes Association advises patients using insulin not to stop taking it. For patients using glargine and considering switching to another form of insulin, the data in these studies make it unclear as to whether any one type of insulin increases the risk of cancer more than other types of insulin. Patients concerned about these studies or their insulin regimen should talk to their doctor and should not stop taking their insulin on the basis of the findings reported here. Insulin is a hormone normally produced by the pancreas that helps the body use glucose for energy. All people with type 1 diabetes need to take insulin to survive; many patients with type 2 diabetes also need to take insulin to control their blood glucose. Glargine insulin, which as been widely used since 2000, is an artificial form of insulin that is typically administered once a day. American Diabetes Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009